|Bid||2.8500 x 800|
|Ask||2.9100 x 2900|
|Day's range||2.8100 - 2.9400|
|52-week range||2.0100 - 4.9600|
|Beta (5Y monthly)||-0.68|
|PE ratio (TTM)||N/A|
|Earnings date||11 Aug 2021 - 16 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
AJRD, BLU, GMBL, LITE, and PSXP have been added to the Zacks Rank #5 (Strong Sell) List on May 25, 2021
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will be participating in a fireside chat at the Jefferies Virtual Healthcare Conference.